eligard™ 45mg injection
lunatus drug store llc united states of america - 1's (1 pre-filled syringe a + 1 pre-filled syringe b) - injection - 45mg - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
eligard™ 7,5mg 7.5mg injection
lunatus drug store llc united states of america - 1's (1 pre-filled syringe a + 1 pre-filled syringe b) - injection - 7.5mg - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
eligard 7.5 mg powder for solution for injection powder and solvent for solution for injection
astellas pharma, netherlands - leuprorelin - powder and solvent for solution for injection - 7.5 mg
eligard 22.5 mg powder for solution for injection powder and solvent for solution for injection
astellas pharma, netherlands - leuprorelin - powder and solvent for solution for injection - 22.5 mg
eligard 45 mg powder for solution for injection powder and solvent for solution for injection
astellas pharma, netherlands - leuprorelin - powder and solvent for solution for injection - 45 mg
needle, hypodermic
mundipharma pty ltd -
eligard 1 month
mundipharma new zealand ltd - leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin); ; ; leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) - injection with diluent - 7.5 mg - active: leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.
eligard 3 month
mundipharma new zealand ltd - leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin); ; ; leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) - injection with diluent - 22.5 mg - active: leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.
eligard 4 month
mundipharma new zealand ltd - leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin); ; ; leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) - injection with diluent - 30 mg - active: leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.
eligard 6 month
mundipharma new zealand ltd - leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin); ; ; leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) - injection with diluent - 45 mg - active: leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.